The clinical control of tumors has been enhanced to varying degrees in solid tumor therapy by blocking LAG3 [201, 202], Tim-3 [203, 204], TIGIT [205, 206], BTLA [207] to improve the adaptability of CD8+ tumor infiltrating lymphocytes (TILs). The gene discussed is HAVCR2; the disease is neoplasm.